ATE460424T1 - Factor viia inhibitore - Google Patents

Factor viia inhibitore

Info

Publication number
ATE460424T1
ATE460424T1 AT99969095T AT99969095T ATE460424T1 AT E460424 T1 ATE460424 T1 AT E460424T1 AT 99969095 T AT99969095 T AT 99969095T AT 99969095 T AT99969095 T AT 99969095T AT E460424 T1 ATE460424 T1 AT E460424T1
Authority
AT
Austria
Prior art keywords
factor viia
viia inhibitors
inhibitors
factor
viia
Prior art date
Application number
AT99969095T
Other languages
English (en)
Inventor
Pavel Safar
Alena Safarova
Peter Wildgoose
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE460424T1 publication Critical patent/ATE460424T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99969095T 1998-09-15 1999-09-02 Factor viia inhibitore ATE460424T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98117506A EP0987274A1 (de) 1998-09-15 1998-09-15 Faktor VIIa Inhibitore
PCT/EP1999/006449 WO2000015658A1 (en) 1998-09-15 1999-09-02 FACTOR VIIa INHIBITORS

Publications (1)

Publication Number Publication Date
ATE460424T1 true ATE460424T1 (de) 2010-03-15

Family

ID=8232644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969095T ATE460424T1 (de) 1998-09-15 1999-09-02 Factor viia inhibitore

Country Status (25)

Country Link
US (1) US6287794B1 (de)
EP (2) EP0987274A1 (de)
JP (1) JP4537581B2 (de)
KR (1) KR100665490B1 (de)
CN (1) CN1203087C (de)
AR (1) AR027814A1 (de)
AT (1) ATE460424T1 (de)
AU (1) AU760580B2 (de)
BR (1) BR9913742A (de)
CA (1) CA2344048A1 (de)
CZ (1) CZ300249B6 (de)
DE (1) DE69942123D1 (de)
HK (1) HK1040253B (de)
HU (1) HUP0103851A3 (de)
ID (1) ID28494A (de)
IL (2) IL141415A0 (de)
MY (1) MY125150A (de)
NO (1) NO328523B1 (de)
NZ (1) NZ510509A (de)
PL (1) PL203227B1 (de)
RU (1) RU2223967C2 (de)
TR (1) TR200100766T2 (de)
TW (1) TW576839B (de)
WO (1) WO2000015658A1 (de)
ZA (1) ZA200101861B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987274A1 (de) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
IL144032A0 (en) * 1999-01-13 2002-04-21 Genentech Inc Serine protease inhibitors
EP1059302A1 (de) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Faktor VIIa Inhibitore
IL148980A0 (en) * 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
EP1095933A1 (de) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH N-Guanidinoalkylamide, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen, die sie enthalten
EP1162194A1 (de) * 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Auf Faktor VIIa inhibitorisch wirkende (Thio)-Harnstoff Verbindungen, Verfahren zu deren Herstellung und deren Verwendung
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
CA2426430C (en) 2000-10-20 2014-10-07 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
PT1345900E (pt) 2000-12-06 2007-03-30 Sanofi Aventis Deutschland Derivados amidina e guanidina como inibidores do factor xa
JP4179878B2 (ja) 2001-02-02 2008-11-12 中外製薬株式会社 ペプチド誘導体
EP1270551A1 (de) * 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Harnstoffverbindungen mit antiproteolytischer Wirkung
EP1314733A1 (de) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
US7604932B2 (en) * 2002-11-13 2009-10-20 Haematologic Technologies, Inc. Assay for tissue factor in a sample
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479675A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazolderivate als Faktor Xa-Inhibitoren
EP1479680A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole-Derivative als Faktor Xa Hemmer
EP1479677A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
AU2004249670A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Acylsulfamide inhibitors of factor VIIa
JP2007500221A (ja) 2003-05-20 2007-01-11 ジェネンテック・インコーポレーテッド 第ＶＩＩａ因子のベンゾフラン阻害剤
EP1568698A1 (de) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
EP2165711B1 (de) * 2004-05-27 2014-05-21 Baxter International Inc. Verfahren zur Behandlung von Blutungsstörungen mittels sulfatierter Polysaccharide
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
KR20100031732A (ko) 2007-07-10 2010-03-24 사노피-아벤티스 항혈전 활성을 갖는 말론아미드 유도체
CN101981050A (zh) * 2008-01-23 2011-02-23 诺沃-诺迪斯克保健股份有限公司 新的凝血因子抑制剂
US9901597B2 (en) 2011-02-04 2018-02-27 Octapharma Ag Method for inactivation/removal of coagulation factors by precipitation
KR20210062649A (ko) * 2018-09-11 2021-05-31 앤비션 에스.알.엘. 펩티드 및 이의 의학적 용도
WO2020053773A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
DK3993876T3 (en) 2019-07-01 2024-12-02 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
AU2022205313A1 (en) 2021-01-06 2023-07-20 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
GB202209228D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
WO1990003390A1 (en) * 1988-09-23 1990-04-05 Corvas, Inc. Peptidyl inhibitors of the initiation of coagulation
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0703923B1 (de) * 1993-06-18 1998-10-07 Nycomed Imaging As Faktor vii-peptide
US5849510A (en) * 1994-04-26 1998-12-15 Selectide Corporation Factor Xa inhibitors
ZA953361B (en) * 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
RU2097033C1 (ru) * 1994-09-30 1997-11-27 Московская государственная академия тонкой химической технологии им.М.В.Ломоносова Имидазолсодержащие ингибиторы катепсин g-индуцированной агрегации тромбоцитов
US5837684A (en) * 1995-06-07 1998-11-17 Nycomed Imaging As Peptides
ES2186874T3 (es) * 1996-02-22 2003-05-16 Bristol Myers Squibb Pharma Co Analogos de m-amidinofenilo como inhibidores del factor xa.
EP0987274A1 (de) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore

Also Published As

Publication number Publication date
CA2344048A1 (en) 2000-03-23
NO20011293L (no) 2001-05-04
IL141415A (en) 2006-09-05
KR20010075130A (ko) 2001-08-09
EP0987274A1 (de) 2000-03-22
HUP0103851A2 (hu) 2002-04-29
CN1318069A (zh) 2001-10-17
TW576839B (en) 2004-02-21
PL346781A1 (en) 2002-02-25
CZ300249B6 (cs) 2009-04-01
CZ2001914A3 (en) 2001-06-13
ID28494A (id) 2001-05-31
WO2000015658A1 (en) 2000-03-23
AU5972399A (en) 2000-04-03
AR027814A1 (es) 2003-04-16
JP4537581B2 (ja) 2010-09-01
TR200100766T2 (tr) 2001-10-22
HUP0103851A3 (en) 2002-05-28
DE69942123D1 (de) 2010-04-22
NZ510509A (en) 2002-09-27
BR9913742A (pt) 2001-06-05
NO328523B1 (no) 2010-03-08
US6287794B1 (en) 2001-09-11
ZA200101861B (en) 2001-10-22
NO20011293D0 (no) 2001-03-14
PL203227B1 (pl) 2009-09-30
HK1040253B (zh) 2005-09-02
HK1040253A1 (en) 2002-05-31
EP1114061B1 (de) 2010-03-10
JP2002524571A (ja) 2002-08-06
EP1114061A1 (de) 2001-07-11
KR100665490B1 (ko) 2007-01-10
CN1203087C (zh) 2005-05-25
MY125150A (en) 2006-07-31
AU760580B2 (en) 2003-05-15
RU2223967C2 (ru) 2004-02-20
IL141415A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
DE69942123D1 (de) FACTOR VIIa INHIBITORE
NO20003808D0 (no) Substituerte oksoazaheterosyklylfaktor Xa inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
ATE245142T1 (de) No-synthase inhibitoren
ATE236167T1 (de) P38 inhibitoren
DE69939689D1 (de) Caspase inhibitoren
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
NO20012980D0 (no) Proteaseinhibitorer
NO20012960D0 (no) Farnesylproteintransferase-inhibitorer
EP1124578A4 (de) Neuartige immunadjuvanzien
NO994626L (no) Substituerte benzamider
DE59806475D1 (de) Urokinase-inhibitoren
NO20003814L (no) Trombininhibitorer
PT1189929E (pt) Inibidores do factor viia
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ID28624A (id) Turunan 2-fenilpiran-4-on
DE59902764D1 (de) Antriebsrolle
NO20010085D0 (no) Angiogeneseinhibitorer
FI980759A0 (fi) Taetningskonstruktion foer suglaodan i en sugvals
ID23196A (id) Gandaran untuk lampuflouresen
DK1141559T3 (da) Sprededyvel
DK199900299U3 (da) Dyvel
FI980743A0 (fi) Gap-valsformare i en pappersmaskin
FI3785U1 (fi) Puupaneeli
UA2621S (uk) Шпала

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties